Selection of an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory system of mice infected experimentally

Capparelli, Rosanna; Ventimiglia, Ilaria; Roperto, Sante; Fenizia, D.; Iannelli, Domenico

doi:10.1111/j.1469-0691.2005.01340.x

Cited by 53 publications

(44 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The observed frequency of phage-resistant bacteria was 1.3 ϫ 10 Ϫ8 Ϯ 4.16 ϫ 10 Ϫ9 . The above results confirm previous studies (8,11,32) indicating that phage resistance is a rare event, perhaps rarer than antibiotic resistance (11,32).…”

Section: Downloaded Fromsupporting

confidence: 92%

“…This problem, originally solved by Merril et al (25), was addressed again recently, with the devising of a protocol which permitted isolation of a phage mutant (specific for Escherichia coli O157:H7) persisting in the mouse circulation for over 1 month (8). The protocol also proved successful in the present study and very likely is of general applicability.…”

Section: Discussionmentioning

confidence: 64%

“…One of the limitations of phage therapy is the rapid clearance of phages by the reticuloendothelial system (14,25,35). In vivo amplification of phages in the presence of the bacterial host has been shown to favor the emergence of rare phage mutants able to persist in the mouse circulation (8). Therefore, four mice were injected intraperitoneally with the wild phage W Sa (10 8 PFU/mouse) and, at 12-h intervals, with four doses of the sensitive host S. aureus A170 (individual dose, 10 7 CFU/ mouse).…”

Section: Phage Isolationmentioning

confidence: 99%

“…A phage strain able to persist in mouse blood was isolated as described previously (8). Briefly, four mice were injected intraperitoneally with phage W Sa (10 8 PFU/mouse) and, at 12-h intervals, with four doses of the sensitive bacterial host S. aureus A170 (10 7 CFU/dose).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Experimental Phage Therapy against Staphylococcus aureus in Mice

Capparelli

Parlato

Borriello

et al. 2007

Antimicrob Agents Chemother

267

206

View full text Add to dashboard Cite

The present study describes a bacteriophage (M Sa ) active against Staphylococcus aureus, including methicillin-resistant staphylococcal strains. When inoculated into mice simultaneously with S. aureus A170 (10 8 CFU/mouse), phage (10 9 PFU) rescued 97% of the mice; when applied to nonlethal (5 ؋ 10 6 CFU/mouse) 10-day infections, the phage also fully cleared the bacteria. The phage M Sa , delivered inside macrophages by S. aureus, kills the intracellular staphylococci in vivo and in vitro. The phage can also prevent abscess formation and reduce the bacterial load and weight of abscesses. These results suggest a potential use of the phage for the control of both local and systemic human S. aureus infections.

show abstract

Section: Downloaded Fromsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 64%

Section: Phage Isolationmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Experimental Phage Therapy against Staphylococcus aureus in Mice

Capparelli

Parlato

Borriello

et al. 2007

Antimicrob Agents Chemother

267

206

View full text Add to dashboard Cite

show abstract

“…There are reports available in literature where phages have been used to treat variety of bacterial infections in animal model systems [29][30][31][32][33][34][35][36][37], the information in this regard to treat burn wound infection is scanty. Soothill [38] demonstrated the ability of phages to prevent rejection of skin grafts in guinea pigs.…”

Section: Discussionmentioning

confidence: 99%

Bacteriophage Treatment of Burn Wound Infection Caused by Pseudomonas aeruginosa PAO in BALB/c Mice

Kumari¹,

Harjai²,

Chhibber³

2009

Am. J. Biomed. Sci.

View full text Add to dashboard Cite

Therapeutic potential of five purified and well characterized bacteriophages (Pa29, Pa30, Pa31, Pa33 and Pa34) was evaluated in thermally injured and Pseudomonas aeruginosa PAO infected mice. Efficacy of five P. aeruginosa phages was assessed on the basis of percentage survival of phage treated mice. Toxicity evaluation of all the phages, showed them to be non toxic as no sign of morbidity and mortality was observed in phage treated mice. Survival and stability of Pseudomonas specific phages was evaluated in mice and maximum phage count in various organs was obtained at 3 h which persisted till 24 h and no phage could be detected at 36 h post inoculation. The results of the study indicate that a single dose of phages intraperitoneally (i.p.) at highest multiplicity of infection (MOI) of 900, did not provide any protection from P. aeruginosa PAO induced burn wound infection in mice. Since a single application of Pseudomonas specific phages did not restrict the infection in thermally injured mice by P. aeruginosa PAO, the experiment was repeated by administering these phages at 24 h intervals, starting immediately after the infection up to 72 h at above mentioned MOI, even then no protection was observed in phage treated groups and results were comparable to control groups with 100% mortality (P>0.05). The results of the present study show that, phages belonging to Podoviridae family, order Caudovirales were not effective in protecting P. aeruginosa infected thermally injured mice.

show abstract

Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review

Dąbrowska

2019

Medicinal Research Reviews

245

212

View full text Add to dashboard Cite

Bacteriophages are not forgotten viruses anymore: scientists and practitioners seek to understand phage pharmacokinetics in animals and humans, investigating bacteriophages as therapeutics, nanocarriers or microbiome components. This review provides a comprehensive overview of factors that determine phage circulation, penetration, and clearance, and that in consequence determine phage applicability for medicine. It makes use of experimental data collected by the phage community so far (PubMed 1924‐2016, including non‐English reports), combining elements of critical and systematic review. This study covers phage ability to enter a system by various routes of administration, how (and if) the phage may access various tissues and organs, and finally what mechanisms determine the courses of phage clearance. The systematic review method was applied to analyze (i) phage survival in the gut (gut transit) and (ii) phage ability to enter the mammalian system by many administration routes. Aspects that have not yet been covered by a sufficient number of reports for mathematical analysis, as well as mechanisms underlying trends, are discussed in the form of a critical review. In spite of the extraordinary diversity of bacteriophages and possible phage applications, the analysis revealed that phage morphology, phage specificity, phage dose, presence of sensitive bacteria or the characteristics of treated individuals (age, taxonomy) may affect phage bioavailability in animals and humans. However, once phages successfully enter the body, they reach most organs, including the central nervous system. Bacteriophages are cleared mainly by the immune system: innate immunity removes phages even when no specific response to bacteriophages has yet developed.

show abstract

Selection of an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory system of mice infected experimentally

Cited by 53 publications

References 38 publications

Experimental Phage Therapy against Staphylococcus aureus in Mice

Experimental Phage Therapy against Staphylococcus aureus in Mice

Bacteriophage Treatment of Burn Wound Infection Caused by Pseudomonas aeruginosa PAO in BALB/c Mice

Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review

Contact Info

Product

Resources

About